Nasal biomarker testing to rule out viral respiratory infection and triage samples: a test performance study

The COVID-19 pandemic revealed an urgent need for practical screening tests to rule out respiratory virus infection, both for managing outbreaks and for routine screening in high-risk settings. PCR is the gold standard test for respiratory virus diagnosis but requires specialised equipment, uses dif...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	EBioMedicine Ročník 117; s. 105820
Hlavní autori:	Amat, Julien A.R., Dudgeon, Sarah N., Cheemarla, Nagarjuna R., Watkins, Timothy A., Green, Alex B., Young, H. Patrick, Peaper, David R., Landry, Marie L., Schulz, Wade L., Foxman, Ellen F.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 01.07.2025 Elsevier
Predmet:	Adolescent Adult Advanced Basic Science Aged Biomarkers - analysis Biomarkers - metabolism Chemokine CXCL10 - analysis Chemokine CXCL10 - metabolism Child Child, Preschool COVID-19 COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - virology CXCL10 Female Host biomarker Host response diagnostics Humans Infant Internal Medicine IP-10 Male Middle Aged Nasal Mucosa - metabolism Nasal Mucosa - virology Nasopharynx - virology Respiratory Tract Infections - diagnosis Respiratory Tract Infections - metabolism Respiratory Tract Infections - virology Respiratory virus screening SARS-CoV-2 - isolation & purification Triage Virus Diseases - diagnosis Virus Diseases - virology Young Adult COVID-19 Respiratory virus screening CXCL10 Host biomarker IP-10 Host response diagnostics
ISSN:	2352-3964, 2352-3964
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	The COVID-19 pandemic revealed an urgent need for practical screening tests to rule out respiratory virus infection, both for managing outbreaks and for routine screening in high-risk settings. PCR is the gold standard test for respiratory virus diagnosis but requires specialised equipment, uses different assays for each virus, and often excludes emerging viruses. The goal of this study was to evaluate a pan-viral host biomarker to rule out respiratory virus infection. We used CXCL10, a cytokine induced in the nasal mucosa in response to diverse respiratory viruses. We compared immunoassay for CXCL10 to respiratory virus PCR panel results in 1088 nasopharyngeal samples from adults and children with an overall viral prevalence of 32.6% by PCR. Using this data, we mathematically modelled the impact of CXCL10 biomarker testing on patient triage and resource savings at different viral prevalences. We also explored clinical features associated with false negatives using automated data extraction from electronic medical records. CXCL10 accurately predicted virus positivity (A.U.C. 0.87, 95% C.I. 0.85–0.90). Mathematical modelling predicted that CXCL10 screening would enable a significant reduction in PCR testing, especially when viral prevalence is low (e.g. 92% of samples testing negative when viral prevalence is 5%, NPV = 0.975). Outlier analysis identified specific chemotherapeutic drugs and low viral load as features associated with false negatives. These results demonstrate the utility of a nasopharyngeal biomarker to rule out respiratory infection, with potential applications in outbreak management and/or routine screening in high-risk settings. Yale-New Haven Hospital Innovation Fund and NIH.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Contributed equally. Current affiliation: Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA, 19104. Current affiliation: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA, 98195.
ISSN:	2352-3964 2352-3964
DOI:	10.1016/j.ebiom.2025.105820